Xbrane says recruitment is complete in the pivotal study of its nivolumab biosimilar candidate. The company has yet to disclose results or a regulatory timetable.
In Phase 1 of the CARMA trial, ELC-301 produced complete metabolic responses in eight of 12 heavily pretreated patients with B-cell lymphoma. Six remained in complete response at their latest assessment.
Researchers are breaking down old barriers by enrolling patients with HIV-associated lymphoma in CAR T and bispecific antibody trials. This shift is forcing a rethink of who gets access to advanced cancer immunotherapies.
Clinical operations teams are using AI simulations to spot enrollment swings and operational threats early, giving them a sharper edge as trial complexity climbs.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
